Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and Cytokinetics

Thursday, September 21, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 21, 2017 /PRNewswire/ --

If you want a Stock Review on AVIR, BPMC, CALA, or CYTK then come over

to and sign up for your free customized report today. On Wednesday, September 20, 2017, the NASDAQ Composite ended the trading session at 6,456.04, down 0.08%; the Dow Jones Industrial
Average edged 0.19% higher, to finish at 22,412.59; and the S&P 500 closed at 2,508.24, slightly advancing 0.06%. US markets saw five out of nine sectors finishing the day in green and 4 in red. This Thursday, has initiated reports coverage on the following Biotechnology equities: Aviragen Therapeutics Inc. (NASDAQ: AVIR), Blueprint Medicines Corp. (NASDAQ: BPMC), Calithera Biosciences Inc. (NASDAQ: CALA), and Cytokinetics Inc. (NASDAQ: CYTK). Take a look at the free research reports issued today on for these stocks by signing up at:

Aviragen Therapeutics 

Alpharetta, Georgia headquartered Aviragen Therapeutics Inc.'s stock finished Wednesday's session 7.34% lower at $0.63 with a total trading volume of 161,128 shares. The Company's shares have advanced 31.27% in the previous three months. The stock is trading above its 50-day moving average by 3.44%. Additionally, shares of Aviragen Therapeutics, which focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide, have a Relative Strength Index (RSI) of 49.26. Sign up and read the free research report on AVIR at:

Blueprint Medicines 

On Wednesday, shares in Cambridge, Massachusetts headquartered Blueprint Medicines Corp. recorded a trading volume of 358,632 shares. The stock ended the session 3.13% lower at $61.86. The Company's shares have advanced 45.83% in the last month, 34.42% in the previous three months, 111.34% over the last twelve months, and 120.53% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 19.74% and 49.14%, respectively. Moreover, shares of Blueprint Medicines, which develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases, have an RSI of 64.56. The complimentary research report on BPMC can be downloaded at:

Calithera Biosciences 

South San Francisco, California headquartered Calithera Biosciences Inc.'s shares closed the day 2.17% higher at $16.45. The stock recorded a trading volume of 448,950 shares. The Company's shares have gained 12.29% in the last month, 418.93% over the last twelve months, and 406.15% since the start of the year. The stock is trading above its 50-day and 200-day moving averages by 5.47% and 42.33%, respectively. Additionally, shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 57.52. Register for free on and access the latest report on CALA at:


Shares in South San Francisco, California headquartered Cytokinetics Inc. finished 0.35% lower at $14.25. The stock recorded a trading volume of 202,971 shares. The Company's shares have advanced 13.55% in the last month, 61.56% over the last twelve months, and 17.28% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.48% and 10.46%, respectively. Furthermore, shares of Cytokinetics, which focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining, have an RSI of 53.07. Get free access to your research report on CYTK at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store